A Randomized, Controlled, Single-Blind, Multicenter Phase II/III Clinical Trial of PD-1 Inhibitor Combined with Chemoradiotherapy for the Treatment of T1-2N2-3/T3-4N0-3M0 Stage Nasopharyngeal Carcinom